RT Journal Article
SR Electronic
T1 Polymorphism of <em>NAT2, PXR, ABCB1</em>, and <em>GSTT1</em> genes among tuberculosis patients of North Eastern States of India
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.09.21258600
DO 10.1101/2021.06.09.21258600
A1 Heikrujam Nilkanta Meitei
A1 Anupama Pandey
A1 Hossain Md. Faruquee
A1 Maria Thokchom
A1 Sonia Athokpam
A1 Hritusree Guha
A1 Ranjit Das
A1 Sourav Saha
A1 Rukuwe-u Kupa
A1 Wetetsho Kapfo
A1 Joshua Keppen
A1 Amit Kumar Mohapatara
A1 Haripriya Priyadarsini
A1 Arunkumar Singh Koijam
A1 Arunabha Dasgupta
A1 Bidhan Goswami
A1 Aseno Thong
A1 Kezhasino Meru
A1 Wungyong Konyak
A1 Dinesh Gupta
A1 Anjan Das
A1 Vinotsole Khamo
A1 Lokhendro Singh Huidrom
A1 Sunita Haobam
A1 Ranjan Kumar Nanda
A1 Reena Haobam
YR 2021
UL http://medrxiv.org/content/early/2021/06/12/2021.06.09.21258600.abstract
AB Background Anti-tuberculosis drug-induced liver injury (AT-DILI) in tuberculosis (TB) patients has been linked to polymorphisms in genes encoding drug metabolism enzymes and proteins.Objective This study aimed to monitor polymorphisms of NAT2, PXR, ABCB1, and GSTT1 genes in TB patients from three states (Manipur, Tripura, and Nagaland) in the North Eastern Region of India.Methods Genomic DNA was isolated from the whole blood samples of TB patients (n=219; Manipur:139; Tripura: 60; Nagaland: 20). The TaqMan allelic discrimination assay and statistical tools were used to investigate single nucleotide polymorphisms (SNP) patterns in NAT2, PXR, ABCB1, and GSTT1 genes.Results In the study population, ten distinct genotypes of the NAT2 gene and single variation in the PXR, ABCB1, and GSTT1 genes were identified. A strong linkage disequilibrium (LD) was observed between rs1801280 and rs1799931 of the NAT2 gene. Majority of the study populations were intermediate (~46.1%), rest were either slow acetylators (~35.6%) or fast acetylators. Interestingly, ~55% of the TB patients in Tripura were slow acetylators and majority in Manipur and Nagaland were of intermediate acetylator genotypes. For all of the markers investigated, the population had a greater prevalence of ancestral alleles and genotypes. According to a combinational study of the genotypes linked to AT-DILI, ~26.1% of the population possessed the risk genotypes.Conclusion These TB patients from north eastern states of India were found as carriers of the ancestral alleles and genotypes. And the risk for AT-DILI during TB treatment is low. Expanding such studies with additional markers and larger sample sizes will be useful to generate precise population-specific pharmacogenomics details for efficient TB management.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project is funded by the Department of Biotechnology, Ministry of Science and Technology, Govt. of India, New Delhi ( BT/PR23238/NER/95/636/2017 dated 19-03-2018).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethical committees of Jawaharlal Nehru Institute of Medical Sciences (JNIMS)-Imphal, Manipur (Ref No. Ac/04/IEC/JNIMS/2017), Agartala Govt. Medical College (AGMC)-Agartala, Tripura (Ref. No. F.4(6-9)/AGMC/Academic/IEC Committee/2015/8965 dated 25th April 2018); and Naga Hospital Authority (NHAK)-Kohima, Nagaland (NHAK/HLRC-008/2012 dated 17th May 2017), Manipur University (MU), (Ref No. Ac/IHEC/MU/003/2017) and International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi (IEC/IRB No. ICGEB/IEC/2018/06).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data related to the manuscript are available with the authors.